Abstract
C1q nephropathy, first proposed by Jennette and Hipp [Am J Clin Pathol 83:415-420, 1985; Am J Kidney Dis 6:103-110, 1985], was described as a distinct glomerular disease entity characterized by extensive mesangial deposition of C1q, with associated mesangial immune complexes, and the absence of any clinical and laboratory evidence of systemic lupus erythematosus. Now, 20 years since the first report, the disease entity is gradually attaining recognition, particularly in the field of pediatrics. C1q is the subcomponent of C1 in the classical pathway of complement activation. Generally, C1q deposition is caused by the activation of C1 by immunoglobulin G (IgG) and IgM; therefore, C1q nephropathy is considered as an immune complex glomerulonephritis. However, in C1q nephropathy, it remains unclear whether the deposition of C1q in the glomeruli is in response to the deposition of immunoglobulin or immune complex, or whether deposition is non-specific trapping that accompanies increased glomerular protein trafficking associated with proteinuria. Since not only the pathogenesis of C1q deposition in glomeruli but also its significance are still uncertain, it has not yet been established as an independent disease. From recent publications of the clinical and pathological characterizations, C1q nephropathy has been thought to be a subgroup of primary focal segmental glomerular sclerosis. However, many reports describe different symptoms, histopathologies, therapeutic responses and prognoses, suggesting that C1q nephropathy is not a single disease entity, but that it may be a combination of several disease groups. There are many uncertain areas requiring further investigation, though it is hoped that a detailed examination of future cases will clarify the subgroups making up C1q nephropathy and their clinicopathological characteristics, and will lead to the establishment of C1q nephropathy as an independent disease entity.
Similar content being viewed by others
References
Jennette JC, Hipp CG. Immunohistopathologic evaluation of C1q in 800 renal biopsy specimens. Am J Clin Pathol. 1985;83:415–20.
Jennette JC, Hipp CG. C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis. 1985;6:103–10.
Prodinger WM, Würzner R, Stoiber H, Dierich MP. Complement. In: Paul WE, editor. Fundamental immunology. 5th ed. Philadelphia: Lippincott Williams Wilkins; 2003. p. 1077–103.
Walport MJ, Lachmann PJ. Complement. In: Lachmann PJ, Peters SK, Rosen FS, Walport MJ, editors. Clinical aspects of immunology. 5th ed. Boston: Blackwell Scientific Publications; 1993. p. 347–70.
Berger SP, Roos A, Daha MR. Complement and the kidney: what the nephrologists needs to know in 2006? Nephrol Dial Transplant. 2005;20:2613–9.
Brown KM, Sachs SH, Sheerin NS. Mechanisms of disease: the complement system in renal injury—New ways of looking at an old foe. Nat Clin Pract Nephrol. 2007;3:277–86.
Kishore U, Gaboriaud C, Waters P, Shrive AK, Greenhough TJ, Reid KBM, et al. C1q and tumor necrosis factor superfamily: modularity and versatility. Trends Immunol. 2004;25:551–61.
Eggleton P, Tenner AJ, Reid KB. C1q receptors. Clin Exp Immunol. 2000;120:406–12.
van den Dobbelsteen ME, van der Woude FJ, Schroeijers WE, Klar-Mohamad N, van Es LA, Daha MR. Both IgG- and C1q-receptors play a role in the enhanced binding of IgG complexes to human mesangial cells. J Am Soc Nephrol.. 1996;7:573–81.
Davenport A, Maciver AG, Mackenzie JC. C1q nephropathy: do C1q deposits have any prognostic significance in the nephrotic syndrome? Nephrol Dial Transplant. 1992;7:391–6.
Jones E, Magil A. Nonsystemic mesangiopathic glomerulonephritis with “full house”immunofluorescence. Pathological and clinical observation in five patients. Am J Clin Pathol. 1982;78:29–34.
Sharman A, Furness P, Feehally J. Distinguishing C1q nephropathy from lupus nephritis. Nephrol Dial Transplant. 2004;19:1420–6.
Iskandar SS, Browning MC, Lorentz WB. C1q Nephropathy: a pediatric clinicopathologic study. Am J Kidney Dis. 1991;18:459–65.
Markowitz GS, Shwimmer JA, Stokes MB, Nasr S, Seigle RL, Valeri AM, et al. C1q nephropathy: a variant of focal segmental glomerulosclerosis. Kidney Int. 2003;64:1232–40.
Lau KK, Gaber LW, Santos NMD, Wyatt RJ. C1q nephropathy: features at presentation and outcome. Pediatr Nephrol. 2005;20:744–9.
Levart TK, Kenda RB, Cavic MA, Ferluga D, Hvala A, Vizjak A. C1q nephropathy in children. Pediatr Nephrol. 2005;20:1756–61.
Nishida M, Kawakatsu H, Okumura Y, Hamaoka K. C1q nephropathy with asymptomatic urine abnormalities. Pediatr Nephrol. 2005;20:1669–70.
Fukuma Y, Hisano S, Segawa Y, Niimi K, Tsuru N, Kaku Y, et al. Clinicopathologic correlation of C1q nephropathy in children. Am J Kidney Dis. 2006;47:412–8.
Hisano S, Fukuma Y, Segawa Y, Niimi K, Kaku Y, Hatae K, Saitoh T, Takeshita M, Iwasaki H. Clinicopathologic Correlation and Outcome of C1q Nephropathy. Clin J Am Soc Nephrol. 2008;3:1637–43.
Kari JA, Jalalah SM. C1q nephropathy in two young sisters. Pediatr Nephrol. 2008;23:487–90.
Kuwano M, Ito Y, Amamoto Y, Aida K. A case of congenital nephrotic syndrome associated with positive C1q immunofluorescence. Pediatr Nephrol. 1993;7:452–4.
Imai H, Yasuda T, Satoh K, Miura AB, Sugawara T, Nakamoto Y. Pan-nephritis (glomerulonephritis, arteriolitis, and tubulointerstitial nephritis) associated with predominant mesangial C1q deposition and hypocomplementemia: a variant type of C1q nephropathy? Am J Kidney Dis. 1996;27:583–7.
Shappell SB, Myrthil G, Fogo A. An adolescent with relapsing nephrotic syndrome: minimal-change disease versus focal-segmental glomerulosclerosis versus C1q nephropathy. Am J Kidney Dis. 1997;29:966–70.
Sato K, Kudo K, Sakurada T, Yuda F, Sato H, Saito T. Case of glomerular nephritis with C1q uniquely deposited in the mesangial region. Nippon Naika Gakkai Zasshi. 1999;88:1518–20.
Srivastava T, Chadha V, Taboada EM, Alon US. C1q nephropathy presenting as rapidly progressive crescentic glomerulonephritis. Pediatr Nephrol. 2000;14:976–9.
Isaac J, Shihab FS. De novo C1q nephropathy in the renal allograft of a kidney pancreas transplant recipient: BK virus-induced nephropathy? Nephron. 2002;92:431–6.
Sardani Y, Qin K, Haas M, Aronson AJ, Rosenfield RL. Bartter syndrome complicated by immune complex nephropathy. Case report and literature review. Pediatr Nephrol. 2003;18:913–8.
Hashimoto S, Ogawa Y, Ishida T, Mochizuki T, Koike T, Sato H, et al. Steroid-sensitive nephrotic syndrome associated with positive C1q immunofluorescence. Clin Exp Nephrol. 2004;8:266–9.
Krinsky CS, Harris A. An 18-year-old woman with proteinuria and renal insufficiency. C1q nephropathy. Arch Pathol Lab Med. 2006;130:e53–5.
Roberti I, Sachdev S, Aronsky A, Kim DU. C1q nephropathy in a child with a chromosome 13 deletion. Pediatr Nephrol. 2006;21:737–9.
Hanevold C, Mian A, Dalton R. C1q nephropathy in association with Gitelman syndrome: a case report. Pediatr Nephrol. 2006;21:1904–8.
Lim IS, Yun KW, Moon KC, Cheong HI. Proteinuria in a boy with infectious mononucleosis, C1q nephropathy, and Dent’s disease. J Korean Med Sci. 2007;22:928–31.
Bitzan M, Ouahed JD, Krishnamoorthy P, Bernard C. Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution. Pediatr Nephrol. 2008;23:1355–61.
Hisano S, Matsushita M, Fujita T, Uesugi N, Iwasaki H. Activation of the lectin complement pathway in C1q nephropathy. J Am Soc Nephrol. 2006;17:256A. (Abstract).
Lu JH, Teh BK, Wang L, Wang YN, Tan YS, Lai MC, et al. The classical and regulatory functions of C1q in immunity and autoimmunity. Cell Mol Immunol. 2008;5:9–21.
Trendelenburg M. Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin Immunopathol. 2005;27:276–85.
Flierman R, Daha MR. Pathogenic role of anti-C1q autoantibodies in the development of lupus nephritis-a hypothesis. Mol Immunol. 2007;44:133–8.
Churg J, Bernstein J, Glassock RJ. Focal semental glomerulosclerosis. In: Churg J, Bernstein J, Glassock RJ, editors. Renal disease: classification and atlas of glomerular disease. New York: Igaku-Shoin Medical Publishers Inc; 1995. p. 45–65.
Andresdottir MB, Assmann KJ, Hilbrands LB, Wetzels JF. Type I Membranoproliferative glomerulonephritis in a renal allograft: a recurrence induced by a cytomegalovirus infection? Am J Kidney Dis. 2000;35:E6.
Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int. 1990;37:663–76.
Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol. 2004;24:198–211.
Lai AS, Lai KN. Viral nephropathy. Nat Clin Pract Nephrol. 2006;2:254–62.
Alpers CE, Kowalewska J. Emerging paradigms in the renal pathology of viral diseases. Clin J Am Soc Nephrol. 2007;2(Suppl 1):S6–12.
Yamabe H. Hepatitis C virus-associated glomerulonephritis. Nippon Rinsho. 2004;62(Suppl 7):550–3.
Johnson RJ, Willson R, Yamabe H, Couser W, Alpers CE, Wener MH, et al. Renal manifestations of hepatitis C virus infection. Kidney Int. 1994;46:1255–63.
Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with “lupus-like” features: a clinicopathologic study of 14 cases. Kidney Int. 2005;67:1381–90.
Obana M, Nakanishi K, Sako M, Yata N, Nozu K, Tanaka R, et al. Segmental membranous glomerulonephritis in children: comparison with global membranous glomerulonephritis. Clin J Am Soc Nephrol. 2006;1:723–9.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Mii, A., Shimizu, A., Masuda, Y. et al. Current status and issues of C1q nephropathy. Clin Exp Nephrol 13, 263–274 (2009). https://doi.org/10.1007/s10157-009-0159-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-009-0159-5